Cellectis Romainvil (CMVLF) 6.6015 $CMVLF
Cellectis Announces the Closing of EUR20.5 M Share Capital Increase Subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors
Business Wire - Mon Mar 31, 1:31PM CDT
Regulatory News:
Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors
Business Wire - Mon Feb 17, 1:03PM CST
Regulatory News:
US Patent Institutions Recognize the Patentability of Institut Pasteur/Cellectis Early Inventions on Meganucleases
Business Wire - Wed Feb 05, 11:00AM CST
Regulatory News:
Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models
Business Wire - Tue Feb 04, 11:44AM CST
Regulatory News:
Cellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing
Business Wire - Thu Jan 30, 12:00AM CST
Regulatory News:
Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays
Business Wire - Fri Jan 17, 11:00AM CST
Regulatory News:
Cellectis Plant Sciences Announce the Finalization of the First Glycosylation Lines of Their Program
Business Wire - Thu Jan 09, 10:59AM CST
Regulatory News :
Cellectis Reorganizes Its Tools and Services Business Line, in Partnership with Caisse Des Depots, by Contributing Ectycell's Shares to Cellectis Bioresearch
Business Wire - Tue Jan 07, 11:00AM CST
Regulatory News:
Competitor Analysis: CD19-Targeted Therapeutics
M2 - Fri Nov 08, 4:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/m86vdq/competitor) has announced the addition of the "Competitor Analysis: CD19-Targeted Therapeutics" report to their offering. Renewed Interest In CD19 As Target For Antibody And T-Cell Therapeutics The human CD19 antigen is a 95 kd transmembrane glycoprotein. It is specifically expressed in normal and neoplastic B cells, as well as follicular dendritic cells. CD19 serves as a diagnostic marker for B-cell malignancies. Virtually all cases of acute lymphoblastic leukemia (ALL) are CD19 positive. Years ago, naked antibodies have been generated against CD19, but clinical results were not sufficiently satisfactory. With the advent of new technologies to increase effector functions of antibodies and to engineer cytotoxic T-lymphocytes to redirect them to CD19, this target has regained considerably interest in oncology. The present Competitive Intelligence report about CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and T-cell-based therapeutics for the treatment of B-cell hematologic malignancies as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies and T-cells targeting CD19 and with enhanced effector function. In addition, the report lists company-specific R&D pipelines of CD19-Targeted Therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage - additional comments with a hyperlink leading to the source of information. Companies Mentioned - Abramson Cancer Center of the University of Pennsylvania - Affimed Therapeutics - Amgen - AstraZeneca - Baylor College of Medicine - Cancer Research UK - Cellectis - City of Hope Medical Center - Emergent Biosolutions - Fred Hutchinson Cancer Research Center - Glenmark Pharmaceuticals 2 - Immunogen - Immunomedics - MD Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Merck Serono - Montefiore Medical Center - Morphosys - National Cancer Institute - Novartis - Sanofi - Seattle Children's Hospital - Seattle Genetics - University College London - University of Texas Southwestern Medical Center - Xencor For more information visit http://www.researchandmarkets.com/research/m86vdq/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cellectis Group Announces Groundbreaking in Vivo Proof of Concept Testing of Their Flagship UCART19 Product for Curative Therapy of Leukemia
Business Wire - Thu Jul 04, 11:00AM CDT
Regulatory News:
Cellectis Has Successfully Engineered the Genome of Photosynthetic Algae with a View to Biofuel Production
Business Wire - Wed Jun 26, 1:22PM CDT
Regulatory News:
Cellectis SA Combined General Shareholders' Meeting of June 14, 2013
Business Wire - Tue Jun 18, 11:30AM CDT
--Dr Mathieu Simon, Senior Vice President and CEO of Cellectis therapeutics, elected to the Board of Directors of Cellectis SA
Cellectis plant sciences CEO Luc Mathis joins Board of Directors of the French Association for Plant Biotechnology (AFBV)
Business Wire - Thu Jun 06, 11:42AM CDT
Regulatory News:
iPS Cells Differentiation patent landscape (2013-03)
M2 - Tue Jun 04, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f253bc/ips_cells) has announced the addition of the "iPS Cells Differentiation patent landscape (2013-03)" report to their offering. Many diseases such as cardiovascular disorders, diabetes or neurodegenerative diseases are the consequences of dysfunction of specific cells. Strategies were developed to repair or regenerate the damaged tissues using differentiated cells out of stem cells. However, ethical and scientific issues are related to the use of embryonic stem cells. In this context, induced pluripotent stem cells (iPS) appear as a promising approach. The patient's somatic cells are first dedifferentiated into iPS cells and then redifferentiated into the cell of interest. This revolutionary technology represents major scientific, societal and economic challenges and was recently rewarded by a Nobel Prize in Physiology and Medicine to Prof. Shinya Yamanaka and Prof. John Gurdon. With over 1000 patent families qualified and analyzed out of a pool of 3000 patent families, we have analysed: - The iPS cells generation patent landscape The analysis of this patent landscape shows a strong complexity of the environment and demonstrates the ability of institutional players to develop a consistent IP strategy like the one from Kyoto university. Some major players already present in 2011 increased sharply their filings: the Kyoto university, the Chinese Academy of Sciences, the laboratories of US government. New entrants have filed numerous patent applications in the last years: Korea university, AIST, Cellular Dynamics, Salk Institute and A*STAR (SG). - The iPS cells differentiation patent landscape As for the thematic iPS cells generation, the main players are mainly institutional (23 institutional applicants in the top 30) with the university of Kyoto and the laboratories of the US government at the first two places. However, industrial applicants from all over the world clearly positioned themselves on the thematic such as Cellular Dynamics (US), Cellectis (FR) or Viacyte (US). The technological breakdowns presented in this study had shown specific positioning of the players through their patent applications notably regarding the type of cell obtained from the differentiation of iPS cells. Cardiovascular, neural, pancreatic cells are the most claimed by the applicants, this corresponding to the main pathologies observed nowadays. Hepatic cells are also often claimed notably for the establishment of toxicology studies. - The iPS cells database Additionally, all patents dealing with iPS cells but who were concerning neither generation nor differentiation (thus all patents related to culture, selection, isolation, etc) were grouped together in a database to get a full overview of the iPS landscape. REASONS TO BUY: These patent landscapes provide you a comprehensive panorama of the intellectual property overview and help you: - Identify key inventors and players involved in the generation and differentiation of iPS cells - Understand their positioning, the collaboration networks and their dynamics - Analyze their IP strategy - Position your company's R&D and IP portfolio? - Discover new trends and emerging topics A three months access to the corresponding patent database, dynamic and interactive, is also included. For more information visit http://www.researchandmarkets.com/research/f253bc/ips_cells About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
TAL-effector Nuclease: The USPTO Issues a Third Patent Licensed to Cellectis
Business Wire - Tue May 28, 11:28AM CDT
Regulatory News:
Cellectis: Compact TALEN(TM): the next generation of TAL effector nucleases
Business Wire - Tue May 21, 11:00AM CDT
Regulatory News:
Cellectis: TAL-effector nuclease: Issuance by the USPTO of Two New Patents
Business Wire - Thu May 16, 11:34AM CDT
Regulatory News:
Precision BioSciences Wins Patent Infringement Lawsuit against Cellectis
Business Wire - Mon May 06, 3:00AM CDT
Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has won a patent infringement lawsuit against Cellectis SA. A jury in the United States District Court for the District of Delaware found that all of the claims of Cellectis' U.S. Pat. No. 7,897,372 ("the '372 patent"
that were asserted against Precision are invalid and that Precision did not literally infringe the asserted claims.
David Sourdive, Vice President of Corporate Development at Cellectis, has been appointed by French Foreign Trade Minister Nicole Bricq to boost France's export performance in the health sector
Business Wire - Thu May 02, 12:00AM CDT
Regulatory News:
Cellectis: 2012 financial results
Business Wire - Mon Apr 29, 11:52AM CDT
--Focus on executing growth strategy
Cellectis Announces the Closing of EUR20.5 M Share Capital Increase Subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors
Business Wire - Mon Mar 31, 1:31PM CDT
Regulatory News:
Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors
Business Wire - Mon Feb 17, 1:03PM CST
Regulatory News:
US Patent Institutions Recognize the Patentability of Institut Pasteur/Cellectis Early Inventions on Meganucleases
Business Wire - Wed Feb 05, 11:00AM CST
Regulatory News:
Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models
Business Wire - Tue Feb 04, 11:44AM CST
Regulatory News:
Cellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing
Business Wire - Thu Jan 30, 12:00AM CST
Regulatory News:
Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays
Business Wire - Fri Jan 17, 11:00AM CST
Regulatory News:
Cellectis Plant Sciences Announce the Finalization of the First Glycosylation Lines of Their Program
Business Wire - Thu Jan 09, 10:59AM CST
Regulatory News :
Cellectis Reorganizes Its Tools and Services Business Line, in Partnership with Caisse Des Depots, by Contributing Ectycell's Shares to Cellectis Bioresearch
Business Wire - Tue Jan 07, 11:00AM CST
Regulatory News:
Competitor Analysis: CD19-Targeted Therapeutics
M2 - Fri Nov 08, 4:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/m86vdq/competitor) has announced the addition of the "Competitor Analysis: CD19-Targeted Therapeutics" report to their offering. Renewed Interest In CD19 As Target For Antibody And T-Cell Therapeutics The human CD19 antigen is a 95 kd transmembrane glycoprotein. It is specifically expressed in normal and neoplastic B cells, as well as follicular dendritic cells. CD19 serves as a diagnostic marker for B-cell malignancies. Virtually all cases of acute lymphoblastic leukemia (ALL) are CD19 positive. Years ago, naked antibodies have been generated against CD19, but clinical results were not sufficiently satisfactory. With the advent of new technologies to increase effector functions of antibodies and to engineer cytotoxic T-lymphocytes to redirect them to CD19, this target has regained considerably interest in oncology. The present Competitive Intelligence report about CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and T-cell-based therapeutics for the treatment of B-cell hematologic malignancies as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies and T-cells targeting CD19 and with enhanced effector function. In addition, the report lists company-specific R&D pipelines of CD19-Targeted Therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage - additional comments with a hyperlink leading to the source of information. Companies Mentioned - Abramson Cancer Center of the University of Pennsylvania - Affimed Therapeutics - Amgen - AstraZeneca - Baylor College of Medicine - Cancer Research UK - Cellectis - City of Hope Medical Center - Emergent Biosolutions - Fred Hutchinson Cancer Research Center - Glenmark Pharmaceuticals 2 - Immunogen - Immunomedics - MD Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Merck Serono - Montefiore Medical Center - Morphosys - National Cancer Institute - Novartis - Sanofi - Seattle Children's Hospital - Seattle Genetics - University College London - University of Texas Southwestern Medical Center - Xencor For more information visit http://www.researchandmarkets.com/research/m86vdq/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cellectis Group Announces Groundbreaking in Vivo Proof of Concept Testing of Their Flagship UCART19 Product for Curative Therapy of Leukemia
Business Wire - Thu Jul 04, 11:00AM CDT
Regulatory News:
Cellectis Has Successfully Engineered the Genome of Photosynthetic Algae with a View to Biofuel Production
Business Wire - Wed Jun 26, 1:22PM CDT
Regulatory News:
Cellectis SA Combined General Shareholders' Meeting of June 14, 2013
Business Wire - Tue Jun 18, 11:30AM CDT
--Dr Mathieu Simon, Senior Vice President and CEO of Cellectis therapeutics, elected to the Board of Directors of Cellectis SA
Cellectis plant sciences CEO Luc Mathis joins Board of Directors of the French Association for Plant Biotechnology (AFBV)
Business Wire - Thu Jun 06, 11:42AM CDT
Regulatory News:
iPS Cells Differentiation patent landscape (2013-03)
M2 - Tue Jun 04, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f253bc/ips_cells) has announced the addition of the "iPS Cells Differentiation patent landscape (2013-03)" report to their offering. Many diseases such as cardiovascular disorders, diabetes or neurodegenerative diseases are the consequences of dysfunction of specific cells. Strategies were developed to repair or regenerate the damaged tissues using differentiated cells out of stem cells. However, ethical and scientific issues are related to the use of embryonic stem cells. In this context, induced pluripotent stem cells (iPS) appear as a promising approach. The patient's somatic cells are first dedifferentiated into iPS cells and then redifferentiated into the cell of interest. This revolutionary technology represents major scientific, societal and economic challenges and was recently rewarded by a Nobel Prize in Physiology and Medicine to Prof. Shinya Yamanaka and Prof. John Gurdon. With over 1000 patent families qualified and analyzed out of a pool of 3000 patent families, we have analysed: - The iPS cells generation patent landscape The analysis of this patent landscape shows a strong complexity of the environment and demonstrates the ability of institutional players to develop a consistent IP strategy like the one from Kyoto university. Some major players already present in 2011 increased sharply their filings: the Kyoto university, the Chinese Academy of Sciences, the laboratories of US government. New entrants have filed numerous patent applications in the last years: Korea university, AIST, Cellular Dynamics, Salk Institute and A*STAR (SG). - The iPS cells differentiation patent landscape As for the thematic iPS cells generation, the main players are mainly institutional (23 institutional applicants in the top 30) with the university of Kyoto and the laboratories of the US government at the first two places. However, industrial applicants from all over the world clearly positioned themselves on the thematic such as Cellular Dynamics (US), Cellectis (FR) or Viacyte (US). The technological breakdowns presented in this study had shown specific positioning of the players through their patent applications notably regarding the type of cell obtained from the differentiation of iPS cells. Cardiovascular, neural, pancreatic cells are the most claimed by the applicants, this corresponding to the main pathologies observed nowadays. Hepatic cells are also often claimed notably for the establishment of toxicology studies. - The iPS cells database Additionally, all patents dealing with iPS cells but who were concerning neither generation nor differentiation (thus all patents related to culture, selection, isolation, etc) were grouped together in a database to get a full overview of the iPS landscape. REASONS TO BUY: These patent landscapes provide you a comprehensive panorama of the intellectual property overview and help you: - Identify key inventors and players involved in the generation and differentiation of iPS cells - Understand their positioning, the collaboration networks and their dynamics - Analyze their IP strategy - Position your company's R&D and IP portfolio? - Discover new trends and emerging topics A three months access to the corresponding patent database, dynamic and interactive, is also included. For more information visit http://www.researchandmarkets.com/research/f253bc/ips_cells About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
TAL-effector Nuclease: The USPTO Issues a Third Patent Licensed to Cellectis
Business Wire - Tue May 28, 11:28AM CDT
Regulatory News:
Cellectis: Compact TALEN(TM): the next generation of TAL effector nucleases
Business Wire - Tue May 21, 11:00AM CDT
Regulatory News:
Cellectis: TAL-effector nuclease: Issuance by the USPTO of Two New Patents
Business Wire - Thu May 16, 11:34AM CDT
Regulatory News:
Precision BioSciences Wins Patent Infringement Lawsuit against Cellectis
Business Wire - Mon May 06, 3:00AM CDT
Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has won a patent infringement lawsuit against Cellectis SA. A jury in the United States District Court for the District of Delaware found that all of the claims of Cellectis' U.S. Pat. No. 7,897,372 ("the '372 patent"
that were asserted against Precision are invalid and that Precision did not literally infringe the asserted claims. David Sourdive, Vice President of Corporate Development at Cellectis, has been appointed by French Foreign Trade Minister Nicole Bricq to boost France's export performance in the health sector
Business Wire - Thu May 02, 12:00AM CDT
Regulatory News:
Cellectis: 2012 financial results
Business Wire - Mon Apr 29, 11:52AM CDT
--Focus on executing growth strategy
